for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Galapagos NV

GLPG.O

Latest Trade

191.35USD

Change

-0.00(-0.00%)

Volume

141,539

Today's Range

190.13

 - 

192.89

52 Week Range

85.00

 - 

192.89

As of on the Euronext Amsterdam Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
191.35
Open
190.39
Volume
141,539
3M AVG Volume
8.41
Today's High
192.89
Today's Low
190.13
52 Week High
192.89
52 Week Low
85.00
Shares Out (MIL)
61.95
Market Cap (MIL)
11,206.41
Forward P/E
-37.00
Dividend (Yield %)
--

Next Event

Galapagos NV at Svb Leerink LLC Non-Deal Roadshow - New York, Boston

Latest Developments

更多

Galapagos Q3 Net Result Turns To Profit Of 265.3 Million Euros

Hitgen Enters Into Dna-Encoded Library Based Drug Discovery Research Collaboration With Galapagos NV

Galapagos Increases Share Capital Through Warrant Exercises

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Galapagos NV

Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.

Industry

Biotechnology & Drugs

Contact Info

Generaal De Wittelaan 3

+32.15.342900

http://www.glpg.com

Executive Leadership

Onno van de Stolpe

Chairman of the Executive Committee, Chief Executive Officer, Executive Director

Rajesh B. Parekh

Non-Executive Chairman of the Board

Bart Filius

Member of the Executive Committee, Chief Financial Officer, Chief Operating Officer

Piet Wigerinck

Member of the Executive Committee, Chief Scientific Officer

Walid Abi-Saab

Member of the Executive Committee, Chief Medical Officer

Key Stats

2.00 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.2K

2017

0.2K

2018

0.3K

2019(E)

0.3K
EPS (EUR)

2016

1.180

2017

-2.340

2018

-0.560

2019(E)

-4.690
Price To Earnings (TTM)
39.39
Price To Sales (TTM)
12.95
Price To Book (MRQ)
4.24
Price To Cash Flow (TTM)
38.58
Total Debt To Equity (MRQ)
0.98
LT Debt To Equity (MRQ)
0.78
Return on Investment (TTM)
8.71
Return on Equity (TTM)
7.64

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up